公开(公告)号：EP2150817A1

公开(公告)日：2010-02-10

申请号：EP08767460.2

申请日：2008-04-30

申请人： Progenics Pharmaceuticals, Inc.

发明人： OLSON, William, C. ,  MADDON, Paul, J. ,  PEVEAR, Daniel, C. ,  ISRAEL, Robert, J. ,  MURGA, Jose, D.

IPC分类号： G01N33/53

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2812 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76

摘要： This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves achieves an average maximum decrease of viral load in the subject of at least 1.83 log10 to 2.5 log10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log10 at about nine days following administration of the CCR5 receptor antagonist. The viral load reducing dose results in a suppression of mean viral load by 1.0 log10 within about four days following administration of the CCR5 receptor antagonist, and suppression of viral load in the subject persists at or below a level of reduction of 1.0 log10 for about two to three weeks. This invention also provides a method of elevating CD4+ cell count in an HIV-1 -infected human subject which comprises administering to the subject at a predefined interval an effective HIV-1 viral load-reducing dose of a humanized antibody designated PRO 140, or an anti-CCR5 receptor monoclonal antibody.

公开(公告)号：EP1910573A2

公开(公告)日：2008-04-16

申请号：EP06788240.7

申请日：2006-07-21

申请人： PROGENICS PHARMACEUTICALS, INC.

发明人： OLSON, William, C. ,  MADDON, Paul, J. ,  PEVEAR, Daniel, C. ,  ISRAEL, Robert, J. ,  MURGA, Jose, D.

IPC分类号： C12Q1/68 ,  G01N33/53

CPC分类号： A61K39/39 ,  A61K31/351 ,  A61K31/4178 ,  A61K31/46 ,  A61K31/496 ,  A61K31/506 ,  A61K31/551 ,  A61K31/7072 ,  A61K38/1709 ,  A61K38/195 ,  A61K39/39541 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/55511 ,  C07K16/2866 ,  C07K2317/24 ,  C07K2317/76 ,  C12Q1/701 ,  A61K2300/00

摘要： This method provides a method for reducing HIV-I viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-I viral load- reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-I -associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-I to CCR5+CD4+ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-I comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4+ cells and (ii) inhibits fusion of HIV-I to the subject's CCR5+CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.